One study revealed that 9 patients with unresectable or recurrent HER2-positive gastric cancer achieved partial clinical remission, accompanied by a decrease in tumor markers (CA19-9, CEA) after treatment with the HER2 dendritic cell vaccine. This evidence concerns the gene ERBB2 and neoplasm.